DSCAM and cancer: However, high expression of DSCAM-AS1 and many genes positively correlated with DSCAM-AS1 have been consistently associated with poor clinical outcomes, such as cancer aggression, tamoxifen resistance, higher grade, stage, and metastasis in ER-positive and luminal BC types [4, 28].